Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management

Hickman, 2002, Management of acute optic neuritis, Lancet, 360, 1953, 10.1016/S0140-6736(02)11919-2

Brady, 1999, Optic neuritis in children, J AAPOS, 3, 98, 10.1016/S1091-8531(99)70078-9

Lucchinetti, 1997, Risk factors for developing multiple sclerosis after childhood optic neuritis, Neurology, 49, 1413, 10.1212/WNL.49.5.1413

Wingerchuk, 1999, The clinical course of neuromyelitis optica (Devic’s syndrome), Neurology, 53, 1107, 10.1212/WNL.53.5.1107

Wingerchuk, 2004, Neuromyelitis optica, Front Biosci, 9, 834, 10.2741/1267

Beck, 1993, Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial, Ophthalmology, 100, 691, 10.1016/S0161-6420(13)31589-9

Beck, 1995, What we have learned from the Optic Neuritis Treatment Trial, Ophthalmology, 102, 1504, 10.1016/S0161-6420(95)30839-1

1991, The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial, Arch Ophthalmol, 109, 1673, 10.1001/archopht.1991.01080120057025

Warner, 1997, Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis?, Arch Ophthalmol, 115, 1408, 10.1001/archopht.1997.01100160578009

Zein, 2004, Multiple sclerosis-associated uveitis, Ocul Immunol Inflamm, 12, 137, 10.1080/09273940490895344

Selhorst, 1995, Uhthoff and his symptom, J Neuroophthalmol, 15, 63, 10.1097/00041327-199506000-00002

Scholl, 1991, Uhthoff’s symptom in optic neuritis, Ann Neurol, 30, 180, 10.1002/ana.410300209

McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032

Truyen, 1996, Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis, Neurology, 47, 1469, 10.1212/WNL.47.6.1469

Beck, 1993, Brain magnetic resonance imaging in acute optic neuritis, Arch Neurol, 50, 841, 10.1001/archneur.1993.00540080050013

Guy, 1992, Enhancement and demyelination of the intraorbital optic nerve. Fat suppression magnetic resonance imaging, Ophthalmology, 99, 713, 10.1016/S0161-6420(92)31892-5

Rizzo, 2002, Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy, Ophthalmology, 109, 1679, 10.1016/S0161-6420(02)01148-X

Beck, 1992, A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis, N Engl J Med, 326, 581, 10.1056/NEJM199202273260901

Beck, 1993, The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis, N Engl J Med, 329, 1764, 10.1056/NEJM199312093292403

Trobe, 1999, The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists, Ophthalmology, 106, 2047, 10.1016/S0161-6420(99)90482-7

Beck, 2004, Visual function more than 10 years after optic neuritis, Am J Ophthalmol, 137, 77, 10.1016/S0002-9394(03)00862-6

1997, Visual function 5 years after optic neuritis, Arch Ophthalmol, 115, 1545, 10.1001/archopht.1997.01100160715008

1997, The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial, Neurology, 49, 1404, 10.1212/WNL.49.5.1404

Beck, 1994, The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial, Ophthalmology, 101, 1771, 10.1016/S0161-6420(94)31103-1

Kaufman, 2000, Practice parameter, Neurology, 54, 2039, 10.1212/WNL.54.11.2039

Brusaferri, 2000, Steroids for multiple sclerosis and optic neuritis, J Neurol, 247, 435, 10.1007/s004150070172

Phillips, 1998, Optic neuritis in African Americans, Arch Neurol, 55, 186, 10.1001/archneur.55.2.186

Noseworthy, 2001, A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis, Neurology, 56, 1514, 10.1212/WNL.56.11.1514

Rizzo, 1988, Risk of developing multiple sclerosis after uncomplicated optic neuritis, Neurology, 38, 185, 10.1212/WNL.38.2.185

Beck, 2003, High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis, Arch Ophthalmol, 121, 944, 10.1001/archopht.121.7.944

2001, The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997, Neurology, 57, S36

Beck, 2004, Neurologic impairment 10 years after optic neuritis, Arch Neurol, 61, 1386, 10.1001/archneur.61.9.1386

Goodin, 2002, Disease modifying therapies in multiple sclerosis, Neurology, 58, 169, 10.1212/WNL.58.2.169

Goodin, 2003, The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis, Neurology, 61, 1332, 10.1212/01.WNL.0000095425.84407.39

Rizvi, 2004, Current approved options for treating patients with multiple sclerosis, Neurology, 63, S8, 10.1212/WNL.63.12_suppl_6.S8

Jacobs, 2000, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med, 343, 898, 10.1056/NEJM200009283431301

Beck, 2002, Interferon beta-1a for early multiple sclerosis, Ann Neurol, 51, 481, 10.1002/ana.10148

Comi, 2001, Effect of early interferon treatment on conversion to definite multiple sclerosis, Lancet, 357, 1576, 10.1016/S0140-6736(00)04725-5